Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Open accessThe DOI matches its Crossref record; 105 of the 124 references it cites were found in a registry or an index.
Abstract
Camptothecins are broad-spectrum anticancer drugs that specifically target DNA topoisomerase I (Topo I). The formation of a cleavable drug-Topo I-DNA complex results in lethal double-strand DNA breakage and cell death. However, de novo or acquired clinical resistance to camptothecins is common. Studies of the camptothecin analog irinotecan suggest the following general mechanisms of resistance: (i) variable levels of the enzymes involved in the conversion of irinotecan; (ii) reduced cellular accumulation from active drug efflux; (iii) reduced levels of Topo I expression; (iv) alterations in the structure of Topo I from different mutations; (v) alterations in the cellular response to camptothecin-Topo I-DNA complex formation, which involves proteasome degradation of Topo I and/or enhanced DNA repair; and (vi) activation of the transcription factor nuclear factor kappa B by DNA damage and subsequent suppression of apoptosis. Multiple approaches using pharmacological and biological modulation to circumvent the above mechanisms of resistance have been incorporated into ongoing clinical trials and are expected to enhance the antitumor activity of irinotecan and reduce its systemic toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Carboxylesterase 2 (CES2) is the critical enzyme for the activation of irinotecan, which can catalyze the conversion of irinotecan to the more active form of SN-38 (a topoisomerase inhibitor) [88].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
In the citing paper
“In addition, the amount of TOP-1 bound to DNA is reduced, which may also lead to CRC resistance to irinotecan [88,131].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 4,979
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“Initial approval in the United States was as a second-line treatment for metastatic colorectal cancer, after failure of 5-fluorouracil (5-FU) and leucovorin [2], and more recently it has been approved for use in combination with 5-FU/leucovorin as a first-line treatment for this disease [3, 4].”
BackgroundAn Essential Role for NF-κB in Preventing TNF-α-Induced Cell Death
Beg, A. A., & Baltimore, D. (1996) · Science · doi:10.1126/science.274.5288.782 · Cited by 3,047
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Palombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096
Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB
Baldwin, A. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11991 · Cited by 1,434
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259
Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A., & Kaplan, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1675 · Cited by 1,045
Research works printed but not linked: 8
- Ilson D, Enzinger P, Saltz L et al. Phase II trial of weekly irinotecan + cisplatin in advanced gastric cancer. Proc Am Soc Clin Oncol 1999; 18: 259a (Abstr).
- Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology 1998; 12: 72-78.
- Prados M, Kuhn J, Yung W et al. A phase-I study of CPT-11 given every 3 weeks to patients with recurrent malignant glioma. A North American Brain Tumor Consortium (NABTC) study. Proc Am Soc Clin Oncol 2001; 19: 162 (Abstr 627).
- Kameyama M, Shoichi I, Ohtsuka K et al. Activation and detoxifica- tion of CPT-11 by human lung cancer cells. Proc Am Soc Clin Oncol 2000; 19: 505a (Abstr 1975).
- Villalona-Calero MA, Kuhn JG, Drengler R et al. Pharmaco- logically-based phase I study of mitomycin C (MMC) as a modulator of irinotecan (CPT-11) antitumor activity. Proc Am Soc Clin Oncol 2001; 20: 101a (Abstr 400).
- Kolesar J, Miller J, Duan W, Villalona-Calero M. TI induction in PBMC by mitomycin-C predicts irinotecan response. Proc Am Soc Clin Oncol 2002; 21: 115 (Abstr 456).
- Ratain, 1999, A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB), Proc Am Soc Clin Oncol, 18, 202a
- Takeda, 2001, Prevention of irinotecan (CPT-11)-induced diarrhea by oral alkalization combined with control of defecation in cancer patients, Int J Cancer, 92, 269, 10.1002/1097-0215(200102)9999:9999<::AID-IJC1179>3.0.CO;2-3 · DOI · Paper page
Cited by
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,672
Natural compounds for cancer treatment and prevention
Nobili, S., Lippi, D., Witort, E., Donnini, M., Bausi, L., Mini, E., & Capaccioli, S. (2009) · Pharmacological Research · doi:10.1016/j.phrs.2009.01.017 · Cited by 780
Mechanisms and insights into drug resistance in cancer
Zahreddine, H., & Borden, K. L. B. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00028 · Cited by 660
The challenge of drug resistance in cancer treatment: a current overview
Nikolaou, M., Pavlopoulou, A., Georgakilas, A. G., & Kyrodimos, E. (2018) · Clinical & Experimental Metastasis · doi:10.1007/s10585-018-9903-0 · Cited by 600
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC
Chang, A. (2011) · Lung Cancer · doi:10.1016/j.lungcan.2010.08.022 · Cited by 443
Understanding and targeting resistance mechanisms in cancer
Lei, Z., Tian, Q., Teng, Q., Wurpel, J. N. D., Zeng, L., Pan, Y., & Chen, Z. (2023) · MedComm · doi:10.1002/mco2.265 · Cited by 347
Nuclear export of proteins and drug resistance in cancer
Turner, J. G., Dawson, J., & Sullivan, D. M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.016 · Cited by 350
Targeting Topoisomerase I in the Era of Precision Medicine
Thomas, A., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1089 · Cited by 337
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
CYP2D6 and tamoxifen: DNA matters in breast cancer
Hoskins, J. M., Carey, L. A., & McLeod, H. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2683 · Cited by 322
Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
Panebianco, C., Andriulli, A., & Pazienza, V. (2018) · Microbiome · doi:10.1186/s40168-018-0483-7 · Cited by 298
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
Logan, R. M., Stringer, A. M., Bowen, J. M., Yeoh, A. S.-J., Gibson, R. J., Sonis, S. T., & Keefe, D. M. K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.03.001 · Cited by 279
Irinotecan—Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview
Kciuk, M., Marciniak, B., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144919 · Cited by 266
Principe, D. R., Underwood, P. W., Korc, M., Trevino, J. G., Munshi, H. G., & Rana, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688377 · Cited by 250
NF-κB pathways in the development and progression of colorectal cancer
Patel, M., Horgan, P. G., McMillan, D. C., & Edwards, J. (2018) · Translational Research · doi:10.1016/j.trsl.2018.02.002 · Cited by 250
Hemdan, M., Ali, M. A., Doghish, A. S., Mageed, S. S. A., Elazab, I. M., Khalil, M. M., Mabrouk, M., Das, D. B., & Amin, A. S. (2024) · Sensors · doi:10.3390/s24165143 · Cited by 240
Yu, M., Qi, B., Xiaoxiang, W., Xu, J., & Liu, X. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.04.001 · Cited by 234
Wang, H., Agarwal, P., Zhao, S., Xu, R. X., Yu, J., Lu, X., & He, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.048 · Cited by 218
Li, J., Kuang, Y., Shi, J., Zhou, J., Medina, J. E., Zhou, R., Yuan, D., Yang, C., Wang, H., Yang, Z., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507157 · Cited by 187
Zhang, F., Zhu, G., Jacobson, O., Liu, Y., Chen, K., Yu, G., Ni, Q., Fan, J., Yang, Z., Xu, F., et al. (2017) · ACS Nano · doi:10.1021/acsnano.7b03003 · Cited by 182
Experience with irinotecan for the treatment of malignant glioma
Vredenburgh, J. J., Desjardins, A., Reardon, D. A., & Friedman, H. S. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-075 · Cited by 179
Tumoral Drug Metabolism: Overview and Its Implications for Cancer Therapy
Michael, M., & Doherty, M. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.120 · Cited by 177
Drug resistance, predictive markers and pharmacogenomics in colorectal cancer
Longley, D. B., Allen, W. L., & Johnston, P. G. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.001 · Cited by 171
Chemoresistance in solid tumours
Wilson, T. R., Longley, D. B., & Johnston, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl280 · Cited by 170
Juang, V., Chang, C., Wang, C., Wang, H., & Lo, Y. (2019) · Small · doi:10.1002/smll.201903296 · Cited by 164
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Logan, R. M., Stringer, A. M., Bowen, J. M., Gibson, R. J., Sonis, S. T., & Keefe, D. M. K. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0732-8 · Cited by 157
Novel Mode of Action of Tylophorine Analogs as Antitumor Compounds
Gao, W., Lam, W., Zhong, S., Kaczmarek, C. G., Baker, D. C., & Cheng, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1904 · Cited by 153
Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 161
Camptothecin and Podophyllotoxin Derivatives
Hartmann, J. T., & Lipp, H. (2006) · Drug Safety · doi:10.2165/00002018-200629030-00005 · Cited by 144
Smith, L. M., Willmore, E., Austin, C. A., & Curtin, N. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1224 · Cited by 134
Richardson, G., & Dobish, R. (2007) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155207077335 · Cited by 135
Deciphering cellular states of innate tumor drug responses
Graudens, E., Boulanger, V., Mollard, C., Mariage-Samson, R., Barlet, X., Grémy, G., Couillault, C., Lajémi, M., Piatier-Tonneau, D., Zaborski, P., et al. (2006) · Genome Biology · doi:10.1186/gb-2006-7-3-r19 · Cited by 126
CircRNAs in anticancer drug resistance: recent advances and future potential
Xu, T., Wang, M., Jiang, L., Ma, L., Wan, L., Chen, Q., Wei, C., & Wang, Z. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01240-3 · Cited by 128
Athymic Nude Mice as an Experimental Model for Cancer Treatment
Szadvári, I., Križanová, O., & Babula, P. (2016) · Physiological Research · doi:10.33549/physiolres.933526 · Cited by 131
ATP Citrate Lyase Mediates Resistance of Colorectal Cancer Cells to SN38
Zhou, Y., Bollu, L. R., Tozzi, F., Ye, X., Bhattacharya, R., Gao, G., Dupre, E., Xia, L., Lu, J., Fan, F., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0098 · Cited by 123
Capello, M., Lee, M., Wang, H., Babel, I., Katz, M. H. G., Fleming, J. B., Maitra, A., Wang, H., Tian, W., Taguchi, A., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv132 · Cited by 119
Domínguez‐Álvarez, E., Rácz, B., Marć, M. A., Nasim, M. J., Szemerédi, N., Viktorová, J., Jacob, C., & Spengler, G. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100844 · Cited by 112
Nirmala, P., & Ramanathan, M. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.034 · Cited by 105
Jani, T. S., DeVecchio, J., Mazumdar, T., Agyeman, A., & Houghton, J. A. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.091645 · Cited by 108
Nagayama, A., Ellisen, L. W., Chabner, B. A., & Bardia, A. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0535-0 · Cited by 103
Vong, L. B., Yoshitomi, T., Matsui, H., & Nagasaki, Y. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.03.037 · Cited by 104
Butyrate, a dietary fiber derivative that improves irinotecan effect in colon cancer cells
Encarnação, J. C., Pires, A. S., Amaral, R. A., Gonçalves, T. J., Laranjo, M., Casalta‐Lopes, J., Gonçalves, A. C., Sarmento‐Ribeiro, A. B., Abrantes, A. M., & Botelho, M. F. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.02.018 · Cited by 101
Quantitative interactome analysis reveals a chemoresistant edgotype
Chavez, J. D., Schweppe, D. K., Eng, J. K., Zheng, C., Taipale, A., Zhang, Y., Takara, K., & Bruce, J. E. (2015) · Nature Communications · doi:10.1038/ncomms8928 · Cited by 94
Targeting the p38 MAPK Pathway Inhibits Irinotecan Resistance in Colon Adenocarcinoma
Paillas, S., Boissière‐Michot, F., Bibeau, F., Denouël, A., Mollévi, C., Causse, A., Denis, V., Vié, N., Marzi, L., Cortijo, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2726 · Cited by 106
André, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds465 · Cited by 98
Lin, Y.-J., Lan, Y.-H., Chuang, C., Lu, W.-T., Chan, L., Hsu, P., & Chen, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197111 · Cited by 99
MAPK14/p38α confers irinotecan resistance to TP53-defective cells by inducing survival autophagy
Paillas, S., Causse, A., Marzi, L., de Medina, P., Poirot, M., Denis, V., Vezzio-Vie, N., Espert, L., Arzouk, H., Coquelle, A., et al. (2012) · Autophagy · doi:10.4161/auto.20268 · Cited by 93
Guo, J., Verma, U. N., Gaynor, R. B., Frenkel, E. P., & Becerra, C. R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0366 · Cited by 93
Rhabdomyosarcoma: Current Therapy, Challenges, and Future Approaches to Treatment Strategies
Zarrabi, A., Perrin, D., Kavoosi, M., Sommer, M., Sezen, S., Mehrbod, P., Bhushan, B., Machaj, F., Rosik, J., Kawalec, P., et al. (2023) · Cancers · doi:10.3390/cancers15215269 · Cited by 108
Twelves, C. J., Jové, M., Gombos, A., & Awada, A. H. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.021 · Cited by 100
Elrebehy, M. A., Al-Saeed, S., Gamal, S., El‐Sayed, A., Ahmed, A. A., Waheed, O., Ismail, A., El‐Mahdy, H. A., Sallam, A.-A. M., & Doghish, A. S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.134 · Cited by 86
George, S. L., Lorenzi, F., King, D., Stainczyk, S. A., Campbell, J., Pemberton, H. N., Toprak, U. H., Barker, K. T., Tall, J. R., Costa, B. M. D., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102971 · Cited by 82
Role of Natural Products in Developing Novel Anticancer Agents: A Perspective
Shaik, B. B., Katari, N. K., & Jonnalagadda, S. B. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200535 · Cited by 112
Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin β1/FAK/ERK Signaling
Wu, J.-I., Lin, Y., Tseng, C.-W., Chen, H.-J., & Wang, L. (2019) · Scientific Reports · doi:10.1038/s41598-018-37443-4 · Cited by 78
Bugs and Drugs: Oncolytic Virotherapy in Combination with Chemotherapy
Wennier, S. T., Liu, J., & McFadden, G. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958850 · Cited by 84
Fakih, M., & Wong, R. (2010) · Current Oncology · doi:10.3747/co.v17is1.616 · Cited by 76
Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
Glasgow, S. C., Yu, J., Carvalho, L. P., Shannon, W. D., Fleshman, J. W., & McLeod, H. L. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602330 · Cited by 74
Martin, R. C. G., Howard, J., Tomalty, D., Robbins, K., Pádr, R., Bošnjaković, P., & Tatum, C. (2010) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-010-9937-4 · Cited by 74
In vivo imaging of early stage apoptosis by measuring real-time caspase-3/7 activation
Scabini, M., Stellari, F., Cappella, P., Rizzitano, S., Texidó, G., & Pesenti, E. A. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0553-1 · Cited by 87
Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives
Madani, F., Esnaashari, S. S., Webster, T. J., Khosravani, M., & Adabi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.023 · Cited by 79
Zhang, Q., Zhang, F., Li, S., Liu, R., Jin, T., Dou, Y., Zhou, Z., & Zhang, J. (2019) · Theranostics · doi:10.7150/thno.34377 · Cited by 72
The design, analysis and application of mouse clinical trials in oncology drug development
Guo, S., Jiang, X., Mao, B., & Li, Q.-X. (2019) · BMC Cancer · doi:10.1186/s12885-019-5907-7 · Cited by 68
Ocker, M., Alajati, A., Ganslmayer, M., Zopf, S., L�ders, M., Neureiter, D., Hahn, E. G., Schuppan, D., & Herold, C. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0664-6 · Cited by 75
Darpp-32: a Novel Antiapoptotic Gene in Upper Gastrointestinal Carcinomas
Belkhiri, A., Zaika, A. I., Pidkovka, N. A., Knuutila, S., Moskaluk, C. A., & El-Rifai, W. M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1433 · Cited by 70
Cummings, J., Zelcer, N., Allen, J. D., Yao, D., Boyd, G. W., Malliepaard, M., Friedberg, T., Smyth, J. F., & Jodrell, D. I. (2003) · Biochemical Pharmacology · doi:10.1016/j.bcp.2003.07.019 · Cited by 74
Wang, L., Liu, X., Zhou, Q., Sui, M., Lu, Z., Zhou, Z., Tang, J., Miao, Y., Zheng, M., Wang, W., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.002 · Cited by 68
Gene signatures of drug resistance predict patient survival in colorectal cancer
Zheng, Y., Zhou, J., & Tong, Y. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.45 · Cited by 64
Not Just Antibiotics: Is Cancer Chemotherapy Driving Antimicrobial Resistance?
Papanicolas, L. E., Gordon, D., Wesselingh, S. L., & Rogers, G. B. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.10.009 · Cited by 70
Role of plant derived bioactive compounds against cancer
Roy, A., Datta, S., Bhatia, K. S., Bhumika, Jha, P., & Prasad, R. (2021) · South African Journal of Botany · doi:10.1016/j.sajb.2021.10.015 · Cited by 66
Yang, Z., Luo, H., Cao, Z., Chen, Y., Gao, J., Li, Y., Jiang, Q. Y., Xu, R., & Liu, J. (2016) · Nanoscale · doi:10.1039/c6nr01749e · Cited by 62
A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors
Ryan, D. P., O’Neil, B. H., Supko, J. G., Lima, C. M. R., Dees, E. C., Appleman, L. J., Clark, J. W., Fidias, P., Orlowski, R. Z., Kashala, O., et al. (2006) · Cancer · doi:10.1002/cncr.22280 · Cited by 67
Chang, C., Wang, Y., Zalath, M. B., Liu, D., Cardillo, T. M., & Goldenberg, D. M. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0219 · Cited by 62
Dendrimer-Mediated Delivery of Anticancer Drugs for Colon Cancer Treatment
Rai, D. B., Medicherla, K., Pooja, D., & Kulhari, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030801 · Cited by 63
Substances of Natural Origin in Medicine: Plants vs. Cancer
Gielecińska, A., Kciuk, M., Mujwar, S., Çelik, İ., Kołat, D., Kałuzińska‐Kołat, Ż., & Kontek, R. (2023) · Cells · doi:10.3390/cells12070986 · Cited by 84
Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NF-κB
Yu, M., Tong, X., Qi, B.-Q., Qu, H., Dong, S., Yu, B., ZHANG, N., Tang, N., Wang, L., & Zhang, C. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1762 · Cited by 60
Gandhi, Y., & Morris, M. E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9132-1 · Cited by 66
CRISPR/Cas9 and cancer targets: future possibilities and present challenges
White, M. K., & Khalili, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7104 · Cited by 71
Methylation-mediated gene silencing as biomarkers of gastric cancer: A review
Nakamura, J., Tanaka, T., Kitajima, Y., Noshiro, H., & Miyazaki, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i34.11991 · Cited by 64
MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer
Yu, X., Li, Z., Yu, J. Q., Chan, M. T. V., & Wu, W. K. K. (2015) · Cell Proliferation · doi:10.1111/cpr.12202 · Cited by 62
Cell Death Signaling and Anticancer Therapy
Galluzzi, L., Vitale, I., Vacchelli, E., & Kroemer, G. (2011) · Frontiers in Oncology · doi:10.3389/fonc.2011.00005 · Cited by 64
Single-Antibody, Targeted Nanoparticle Delivery of Camptothecin
Han, H., & Davis, M. E. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300702x · Cited by 58
Mazard, T., Causse, A., Simony, J., Leconet, W., Vezzio-Vie, N., Torro, A., Jarlier, M., Evrard, A., Del Rio, M., Assenat, E., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0966 · Cited by 57
Single-Molecule Detection of Human Topoisomerase I Cleavage−Ligation Activity
Stougaard, M., Lohmann, J. S., Mancino, A., Çelik, S., Andersen, F. F., Koch, J., & Knudsen, B. R. (2008) · ACS Nano · doi:10.1021/nn800509b · Cited by 56
Understanding Cancer’s Defense against Topoisomerase-Active Drugs: A Comprehensive Review
Sharma, N. K., Bahot, A., Sekar, G., Bansode, M., Khunteta, K., Sonar, P. V., Hebale, A., Salokhe, V., & Sinha, B. K. (2024) · Cancers · doi:10.3390/cancers16040680 · Cited by 65
Zoetemelk, M., Ramzy, G. M., Rausch, M., & Nowak-Sliwinska, P. M. (2020) · Molecules · doi:10.3390/molecules25112614 · Cited by 63
Gene Expression Profiling of the Irinotecan Pathway in Colorectal Cancer
Yu, J., Shannon, W. D., Watson, M. A., & McLeod, H. L. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1254 · Cited by 55
Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade
Wang, Z., Li, W., Park, J., Gonzalez, K. M., Scott, A. J., & Lu, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.042 · Cited by 57
Tao, G., Huang, J., Moorthy, B., Wang, C., Hu, M. C., Gao, S., & Ghose, R. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1815705 · Cited by 59
Lo, Y.-L., Chang, C.-H., Wang, C.-S., Yang, M.-H., Lin, A. M.-Y., Hong, C.-J., & Tseng, W.-H. (2020) · Theranostics · doi:10.7150/thno.45164 · Cited by 52
Seo, S., Kim, S., Shin, J., Ham, D.-W., & Shin, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186642 · Cited by 56
Solier, S., Zhang, Y., Ballestrero, A., Pommier, Y. G., & Zoppoli, G. M. (2012) · Current Cancer Drug Targets · doi:10.2174/156800912800190901 · Cited by 56
Yang, Y., Wang, G., Zhu, D., Huang, Y., Luo, Y., Su, P., Chen, X., & Wang, Q. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4044 · Cited by 54
Oyaga-Iriarte, E., Insausti, A., Sayar, O., & Aldaz, A. (2019) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2019.03.004 · Cited by 49
Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review
Molaei, P., Mahaki, H., Manoochehri, H., & Tanzadehpanah, H. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220426124834 · Cited by 49
Paradiso, A., Xu, J., Mangia, A., Chiriatti, A., Simone, G., Zito, A., Montemurro, S., Giuliani, F., Maiello, E., & Colucci, G. (2004) · International Journal of Cancer · doi:10.1002/ijc.20208 · Cited by 48
Molecular-targeted therapies: Lessons from years of clinical development
Rosa, D. D., Ismael, G., Lago, L. D., & Awada, A. H. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.07.019 · Cited by 54
Metadata
- Authors
- Xu, Y., & Villalona-Calero, M. A.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Villalona-Calero, M.A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-12
- Volume
- 13
- Issue
- 12
- Pages
- 1841-1851
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2112055293
- Cited by
- 413
- References
- 124
- Citations by year
- 2026: 25 · 2025: 18 · 2024: 25 · 2023: 40 · 2022: 30 · 2021: 23 · 2020: 24 · 2019: 17 · 2018: 16 · 2017: 22 · 2016: 15 · 2015: 24 · 2014: 13 · 2013: 11 · 2012: 10
- FWCI
- 0.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 6246 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Texas Health Science Center at San Antonio
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- irinotecan, camptothecin, topoisomerase I, drug resistance, drug efflux, proteasomal degradation, DNA repair, NF-κB, apoptosis, anticancer drug metabolism, combination therapy
- MeSH terms
- Irinotecan, Animals, Camptothecin, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Male, Neoplasms, Sensitivity and Specificity, NF-kappa B, Apoptosis, Risk Assessment, Drug Resistance, Neoplasm, Maximum Tolerated Dose, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.